In gene expression profiling studies conducted with samples from CML patients, GAS2 was identified as highly expressed, with a notable upregulation observed during the transition from the chronic phase to the acute phase of the disease 41-43. This evidence concerns the gene GAS2 and chronic myelogenous leukemia, BCR-ABL1 positive.